WALTHAM, Mass., May 13, 2014 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 3:00 p.m. ET in New York. The session will include a company presentation in which the company’s business and financial outlook, strategy and growth prospects will be discussed.
A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in the United States. Along with driving organic growth of its products, AMAG intends to expand its portfolio with additional commercial-stage specialty products. The company is seeking complementary products that leverage the company’s commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. MuGard is a registered trademark of Access Pharmaceuticals, Inc.
CONTACT: AMAG Pharmaceuticals, Inc. Contact:
Katie Payne, 617-498-3303
AMAG Pharmaceuticals, Inc.